parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in platelets	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 22	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 9460

FAXDC2 in dopamine neurons, braak+0.35 (p 0.360) → -0.07 (p 0.859)receipt 9469
FAXDC2 in oligodendrocytes, braak-0.02 (p 0.964) → +0.05 (p 0.893)receipt 9468

receipt 9469: FAXDC2 in dopamine neurons, braak

power: full sample +0.07 (p 0.781, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.741, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.08 (p 0.741, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.18, sign flips 2; without severely affected donors +0.07 (p 0.781, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FAXDC2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9468: FAXDC2 in oligodendrocytes, braak

power: full sample -0.04 (p 0.881, n 18), 95% CI -0.50 to +0.44. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.11 (p 0.652, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.06 (p 0.807, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.07, sign flips 5; without severely affected donors -0.04 (p 0.881, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FAXDC2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts